APVO - Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting
SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates will be presented in poster sessions at the American Association for Cancer Research (AACR) 2019 Annual Meeting, being held in Atlanta, GA, March 29 – April 3, 2019.
| Title: |
| Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody |
| Date/Time: |
| April 1, 2019 – 1:00 pm – 5:00 pm ET |
| Session Title: |
| Therapeutic Antibodies 3 |
| Abstract ID: |
| 2380/4 |
| Title: |
| APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques |
| Date/Time: |
| April 2, 2019 – 8:00 am – 12:00 pm ET |
| Session Title: |
| Late Breaking Research: Immunology 2 |
| Abstract ID: |
| LB199/17 |
Abstracts for the AACR annual meeting are available and can be viewed online at www.aacr.org. Aptevo’s poster presentations will be available on the Investor Relations section of the Company’s website at www.aptevotherapeutics.com when the posters are presented.
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
JurchisonS@apvo.com